Strategic update on the progress and development of Molecure's key clinical projects in 2024 Mar 28, 2025 10:00AM
Molecure and Ocean Biomedical (OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors Oct 15, 2024 07:36AM
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibito Oct 15, 2024 07:30AM
Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs Jul 31, 2024 08:00AM
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights Oct 31, 2023 04:00AM


Sep 29, 2023 06:00AM Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
Jul 21, 2023 03:00AM Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of brea
Jun 23, 2023 03:00AM Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study
Mar 30, 2023 03:00AM Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress
Mar 8, 2023 09:00AM Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
Jan 3, 2023 11:32AM Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio
Dec 5, 2022 06:16AM Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
Nov 28, 2022 09:16AM Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland
Nov 14, 2022 04:00AM Save The Date: Molecure to Host Virtual R&D Day on 7th December 2022
Oct 31, 2022 05:00AM Molecure Third Quarter 2022 Pipeline Highlights and Financial Results
Sep 29, 2022 03:00AM Molecure reports continued pipeline momentum for 6 months ended 30th June 2022
Jun 23, 2022 04:50PM Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01